Tularemia: current diagnosis and treatment options

References

• McCoy GW, Chapin CW. Further observations on a plaguelike disease of rodents with a preliminary note on the causative agent Bacterium tularense. J. Infect. Dis.10, 61–72 (1912).
   Google Scholar
• Dennis DT, Inglesby TV, Henderson DA et al. Tularemia as a biological weapon: medical and public health management. JAMA285, 2763–2773 (2001).
   PubMed Web of Science ®Google Scholar
• Farlow J, Wagner DM, Dukerich M et al.Francisella tularensis in the United States. Emerging Infect. Dis.11, 1835–1841 (2005).
   PubMed Web of Science ®Google Scholar
• Gurycova D. First isolation of Francisella tularensis subsp. tularensis in Europe. Eur. J. Epidemiol.14, 797–802 (1998).
   PubMedGoogle Scholar
• Cross JT, Penn RL. Francisella tularensis (tularemia). In: Principles and Practice of Infectious Diseases. (5th Edition, Volume 2). Mandell GL, Bennett JE, Dolin R (Eds). Churchill Livingstone, Philadelphia, PA, USA 2393–2402 (2000).
   Google Scholar
• Sandstrom G. The tularaemia vaccine. J. Chem. Technol. Biotechnol.59, 315–320 (1994).
   PubMed Web of Science ®Google Scholar
• Burke DS. Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J. Infect. Dis.135, 55–60 (1977).
   PubMed Web of Science ®Google Scholar
• Rohrbach BW, Westerman E, Istre GR. Epidemiology and clinical characteristics of tularemia in Oklahoma, 1979 to 1985. South. Med. J.84, 1091–1096 (1991).
   PubMed Web of Science ®Google Scholar
• Ohara Y, Sato T, Fujita H, Ueno T, Homma M. Clinical manifestations of tularemia in Japan – analysis of 1,355 cases observed between 1924 and 1987. Infection19, 14–17 (1991).
   PubMed Web of Science ®Google Scholar
• Dahlstrand S, Ringertz O, Zetterberg B. Airborne tularemia in Sweden. Scand. J. Infect. Dis.3, 7–16 (1971).
   PubMedGoogle Scholar
• Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore)64, 251–269 (1985).
   PubMed Web of Science ®Google Scholar
• Van Metre TE Jr, Kadull PJ. Laboratory-acquired tularemia in vaccinated individuals: a report of 62 cases. Ann. Intern. Med.50, 621–632 (1959).
   PubMedGoogle Scholar
• Reilly TJ, Baron GS, Nano FE, Kuhlenschmidt MS. Characterization and sequencing of a respiratory burst-inhibiting acid phosphatase from Francisella tularensis. J. Biol. Chem.271, 10973–10983 (1996).
   PubMedGoogle Scholar
• Telepnev M, Golovliov I, Grundstrom T, Tarnvik A, Sjostedt A. Francisella tularensis inhibits Toll-like receptor-mediated activation of intracellular signalling and secretion of TNF-α and IL-1 from murine macrophages. Cell. Microbiol.5, 41–51 (2003).
   PubMed Web of Science ®Google Scholar
• Telepnev M, Golovliov I, Sjostedt A. Francisella tularensis LVS initially activates but subsequently down-regulates intracellular signaling and cytokine secretion in mouse monocytic and human peripheral blood mononuclear cells. Microb. Pathog.38, 239–247 (2005).
   PubMed Web of Science ®Google Scholar
• Hrstka R, Stulik J, Vojtesek B. The role of MAPK signal pathways during Francisella tularensis LVS infection-induced apoptosis in murine macrophages. Microbes Infect.7, 619–625 (2005).
   PubMedGoogle Scholar
• Clemens DL, Lee BY, Horwitz MA. Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect. Immun.72, 3204–3217 (2004).
   PubMed Web of Science ®Google Scholar
• Golovliov I, Baranov V, Krocova Z, Kovarova H, Sjostedt A. An attenuated strain of the facultative intracellular bacterium Francisella tularensis can escape the phagosome of monocytic cells. Infect. Immun.71, 5940–5950 (2003).
   PubMed Web of Science ®Google Scholar
• Lindgren H, Golovliov I, Baranov V, Ernst RK, Telepnev M, Sjostedt A. Factors affecting the escape of Francisella tularensis from the phagolysosome. J. Med. Microbiol.53, 953–958 (2004).
   PubMedGoogle Scholar
• Santic M, Molmeret M, Klose KE, Jones S, Kwaik YA. The Francisella tularensis pathogenicity island protein IglC and its regulator MglA are essential for modulating phagosome biogenesis and subsequent bacterial escape into the cytoplasm. Cell. Microbiol.7, 969–979 (2005).
   PubMed Web of Science ®Google Scholar
• Saslaw S, Eigelsbach HT, Wilson HE, Prior JA, Carhart S. Tularemia vaccine study. I. Intracutaneous challenge. Arch. Intern. Med.107, 689–701 (1961).
   PubMed Web of Science ®Google Scholar
• Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med.107, 702–714 (1961).
   PubMed Web of Science ®Google Scholar
• Bosio CM, Bielefeldt-Ohmann H, Belisle JT. Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J. Immunol.178, 4538–4547 (2007).
   PubMed Web of Science ®Google Scholar
• Bosio CM, Dow SW. Francisella tularensis induces aberrant activation of pulmonary dendritic cells. J. Immunol.175, 6792–6801 (2005).
   PubMed Web of Science ®Google Scholar
• Elkins KL, Cowley SC, Bosio CM. Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect.5, 135–142 (2003).
   PubMed Web of Science ®Google Scholar
• Elkins KL, Rhinehart-Jones TR, Culkin SJ, Yee D, Winegar RK. Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect. Immun.64, 3288–3293 (1996).
   PubMedGoogle Scholar
• Yee D, Rhinehart-Jones TR, Elkins KL. Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J. Immunol.157, 5042–5048 (1996).
   PubMed Web of Science ®Google Scholar
• Forestal CA, Malik M, Catlett SV et al.Francisella tularensis has a significant extracellular phase in infected mice. J. Infect. Dis.196, 134–137 (2007).
   PubMed Web of Science ®Google Scholar
• Tarnvik A. Nature of protective immunity to Francisella tularensis. Rev. Infect. Dis.11, 440–451 (1989).
   PubMedGoogle Scholar
• Ericsson M, Sandstrom G, Sjostedt A, Tarnvik A. Persistence of cell-mediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection. J. Infect. Dis.170, 110–114 (1994).
   PubMed Web of Science ®Google Scholar
• Poquet Y, Kroca M, Halary F et al. Expansion of Vγ9 Vδ2 T cells is triggered by Francisella tularensis-derived phosphoantigens in tularemia but not after tularemia vaccination. Infect. Immun.66, 2107–2114 (1998).
   PubMed Web of Science ®Google Scholar
• Sjostedt A, Conlan JW, North RJ. Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection. Infect. Immun.62, 2779–2783 (1994).
   PubMed Web of Science ®Google Scholar
• Fulop M, Mastroeni P, Green M, Titball RW. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine19, 4465–4472 (2001).
   PubMed Web of Science ®Google Scholar
• Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerging Infect. Dis.8, 833–841 (2002).
   PubMed Web of Science ®Google Scholar
• Kirimanjeswara GS, Golden JM, Bakshi CS, Metzger DW. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J. Immunol.179, 532–539 (2007).
   PubMed Web of Science ®Google Scholar
• Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clin. Microbiol. Rev.15, 631–646 (2002).
   PubMed Web of Science ®Google Scholar
• Petersen JM, Schriefer ME, Gage KL et al. Methods for enhanced culture recovery of Francisella tularensis. Appl. Environ. Microbiol.70, 3733–3735 (2004).
   PubMedGoogle Scholar
• Hepburn MJ, Purcell BK, Lawler JV et al. Live vaccine strain Francisella tularensis is detectable at the inoculation site but not in blood after vaccination against tularemia. Clin. Infect. Dis.43, 711–716 (2006).
   PubMedGoogle Scholar
• Sawyer WD, Dangerfield HG, Hogge AL, Crozier D. Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriol. Rev.30, 542–550 (1966).
   PubMedGoogle Scholar
• Haristoy X, Lozniewski A, Tram C, Simeon D, Bevanger L, Lion C. Francisella tularensis bacteremia. J. Clin. Microbiol.41, 2774–2776 (2003).
   PubMedGoogle Scholar
• Khoury JA, Bohl DL, Hersh MJ, Argoudelis AC, Brennan DC. Tularemia in a kidney transplant recipient: an unsuspected case and literature review. Am. J. Kidney Dis.45, 926–929 (2005).
   PubMedGoogle Scholar
• Reary BW, Klotz SA. Enhancing recovery of Francisella tularensis from blood. Diagn. Microbiol. Infect. Dis.11, 117–119 (1988).
   PubMedGoogle Scholar
• Emanuel PA, Bell R, Dang JL et al. Detection of Francisella tularensis within infected mouse tissues by using a hand-held PCR thermocycler. J. Clin. Microbiol.41, 689–693 (2003).
   PubMedGoogle Scholar
• Versage JL, Severin DD, Chu MC, Petersen JM. Development of a multitarget real-time TaqMan PCR assay for enhanced detection of Francisella tularensis in complex specimens. J. Clin. Microbiol.41, 5492–5499 (2003).
   PubMed Web of Science ®Google Scholar
• Johansson A, Berglund L, Eriksson U et al. Comparative analysis of PCR versus culture for diagnosis of ulceroglandular tularemia. J. Clin. Microbiol.38, 22–26 (2000).
   PubMed Web of Science ®Google Scholar
• Sjostedt A, Eriksson U, Berglund L, Tarnvik A. Detection of Francisella tularensis in ulcers of patients with tularemia by PCR. J. Clin. Microbiol.35, 1045–1048 (1997).
   PubMed Web of Science ®Google Scholar
• Eliasson H, Sjostedt A, Back E. Clinical use of a diagnostic PCR for Francisella tularensis in patients with suspected ulceroglandular tularaemia. Scand. J. Infect. Dis.37, 833–837 (2005).
   PubMed Web of Science ®Google Scholar
• Celebi G, Baruonu F, Ayoglu F et al. Tularemia, a reemerging disease in northwest Turkey: epidemiological investigation and evaluation of treatment responses. Jpn. J. Infect. Dis.59, 229–234 (2006).
   PubMed Web of Science ®Google Scholar
• Gurcan S, Eskiocak M, Varol G et al. Tularemia re-emerging in European part of Turkey after 60 years. Jpn. J. Infect. Dis.59, 391–393 (2006).
   PubMed Web of Science ®Google Scholar
• Kantardjiev TV, Padeshki PI, Ivanov IN. Diagnostic approaches for oculoglandular tularemia- advantages of PCR. Br. J. Ophthalmol.91(9), 1206–1208 (2007).
   PubMed Web of Science ®Google Scholar
• Tomioka K, Peredelchuk M, Zhu X et al. A multiplex polymerase chain reaction microarray assay to detect bioterror pathogens in blood. J. Mol. Diagn.7, 486–494 (2005).
   PubMedGoogle Scholar
• Skottman T, Piiparinen H, Hyytiainen H, Myllys V, Skurnik M, Nikkari S. Simultaneous real-time PCR detection of Bacillus anthracis, Francisella tularensis and Yersinia pestis. Eur. J. Clin. Microbiol. Infect. Dis.26, 207–211 (2007).
   PubMedGoogle Scholar
• Wilson WJ, Erler AM, Nasarabadi SL, Skowronski EW, Imbro PM. A multiplexed PCR-coupled liquid bead array for the simultaneous detection of four biothreat agents. Mol. Cell. Probes19, 137–144 (2005).
   PubMedGoogle Scholar
• Splettstoesser WD, Tomaso H, Al Dahouk S, Neubauer H, Schuff-Werner P. Diagnostic procedures in tularaemia with special focus on molecular and immunological techniques. J. Vet. Med. B Infect. Dis. Vet. Public Health52, 249–261 (2005).
   PubMedGoogle Scholar
• Massey ED, Mangiafico JA. Microagglutination test for detecting and measuring serum agglutinins of Francisella tularensis. Appl. Microbiol.27, 25–27 (1974).
   PubMedGoogle Scholar
• Carlsson HE, Lindberg AA, Lindberg G, Hederstedt B, Karlsson KA, Agell BO. Enzyme-linked immunosorbent assay for immunological diagnosis of human tularemia. J. Clin. Microbiol.10, 615–621 (1979).
   PubMed Web of Science ®Google Scholar
• Waag DM, McKee KT Jr, Sandstrom G et al. Cell-mediated and humoral immune responses after vaccination of human volunteers with the live vaccine strain of Francisella tularensis. Clin. Diagn. Lab. Immunol.2, 143–148 (1995).
   PubMedGoogle Scholar
• Waag DM, Sandstrom G, England MJ, Williams JC. Immunogenicity of a new lot of Francisella tularensis live vaccine strain in human volunteers. FEMS Immunol. Med. Microbiol.13, 205–209 (1996).
   PubMedGoogle Scholar
• Tärnvik A, Chu MC. New approaches to diagnosis and therapy of tularemia. Ann. NY Acad. Sci.1105, 378–404 (2007).
   PubMed Web of Science ®Google Scholar
• Grunow R, Splettstoesser W, McDonald S et al. Detection of Francisella tularensis in biological specimens using a capture enzyme-linked immunosorbent assay, an immunochromatographic handheld assay, and a PCR. Clin. Diagn. Lab. Immunol.7, 86–90 (2000).
   PubMedGoogle Scholar
• Andersson H, Hartmanova B, Back E et al. Transcriptional profiling of the peripheral blood response during tularemia. Genes Immun.7, 503–513 (2006).
   PubMed Web of Science ®Google Scholar
• Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin. Infect. Dis.19, 42–47 (1994).
   PubMed Web of Science ®Google Scholar
• Mason WL, Eigelsbach HT, Little SF, Bates JH. Treatment of tularemia, including pulmonary tularemia, with gentamicin. Am. Rev. Respir. Dis.121, 39–45 (1980).
   PubMedGoogle Scholar
• Cross JT Jr, Schutze GE, Jacobs RF. Treatment of tularemia with gentamicin in pediatric patients. Pediatr. Infect. Dis. J.14, 151–152 (1995).
   PubMedGoogle Scholar
• Penn RL, Kinasewitz GT. Factors associated with a poor outcome in tularemia. Arch. Intern. Med.147, 265–268 (1987).
   PubMedGoogle Scholar
• Cross JT, Jacobs RF. Tularemia: treatment failures with outpatient use of ceftriaxone. Clin. Infect. Dis.17, 976–980 (1993).
   PubMedGoogle Scholar
• Harrell RE Jr, Simmons HF. Pleuropulmonary tularemia: successful treatment with erythromycin. South Med. J.83, 1363–1364 (1990).
   PubMed Web of Science ®Google Scholar
• Tomaso H, Al Dahouk S, Hofer E et al. Antimicrobial susceptibilities of Austrian Francisella tularensis holarctica biovar II strains. Int. J. Antimicrob. Agents26, 279–284 (2005).
   PubMed Web of Science ®Google Scholar
• Russell P, Eley SM, Fulop MJ, Bell DL, Titball RW. The efficacy of ciprofloxacin and doxycycline against experimental tularaemia. J. Antimicrob. Chemother.41, 461–465 (1998).
   PubMedGoogle Scholar
• Overholt EL, Tigertt WD, Kadull PJ et al. An analysis of 42 cases of laboratory-acquired tularemia. Treatment with broad spectrum antibiotics. Am. J. Med.30, 785–806 (1961).
   PubMedGoogle Scholar
• Ikaheimo I, Syrjala H, Karhukorpi J, Schildt R, Koskela M. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J. Antimicrob. Chemother.46, 287–290 (2000).
   PubMed Web of Science ®Google Scholar
• Syrjala H, Schildt R, Raisainen S. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis.10, 68–70 (1991).
   PubMed Web of Science ®Google Scholar
• Piercy T, Steward J, Lever MS, Brooks TJ. In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice. J. Antimicrob. Chemother.56, 1069–1073 (2005).
   PubMedGoogle Scholar
• Steward J, Piercy T, Lever MS, Simpson AJ, Brooks TJ. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. Int. J. Antimicrob. Agents27, 439–443 (2006).
   PubMed Web of Science ®Google Scholar
• Johansson A, Berglund L, Sjostedt A, Tarnvik A. Ciprofloxacin for treatment of tularemia. Clin. Infect. Dis.33, 267–268 (2001).
   PubMed Web of Science ®Google Scholar
• Chocarro A, Gonzalez A, Garcia I. Treatment of tularemia with ciprofloxacin. Clin. Infect. Dis.31, 623 (2000).
   PubMedGoogle Scholar
• Perez-Castrillon JL, Bachiller-Luque P, Martin-Luquero M, Mena-Martin FJ, Herreros V. Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin. Infect. Dis.33, 573–576 (2001).
   PubMed Web of Science ®Google Scholar
• Johansson A, Berglund L, Gothefors L, Sjostedt A, Tarnvik A. Ciprofloxacin for treatment of tularemia in children. Pediatr. Infect. Dis. J.19, 449–453 (2000).
   PubMed Web of Science ®Google Scholar
• Aranda EA. Treatment of tularemia with levofloxacin. Clin. Microbiol. Infect.7, 167–168 (2001).
   PubMed Web of Science ®Google Scholar
• Limaye AP, Hooper CJ. Treatment of tularemia with fluoroquinolones: two cases and review. Clin. Infect. Dis.29, 922–924 (1999).
   PubMedGoogle Scholar
• Luotonen J, Syrjala H, Jokinen K, Sutinen S, Salminen A. Tularemia in otolaryngologic practice. An analysis of 127 cases. Arch. Otolaryngol. Head Neck Surg.112, 77–80 (1986).
   PubMedGoogle Scholar
• Wherry WB, Lamb BH. Infection of man with Bacterium tularense. J. Infect. Dis.15, 331–340 (1914).
   Google Scholar
• Christova I, Velinov T, Kantardjiev T, Galev A. Tularaemia outbreak in Bulgaria. Scand. J. Infect. Dis.36, 785–789 (2004).
   PubMed Web of Science ®Google Scholar
• Helvaci S, Gedikoglu S, Akalin H, Oral HB. Tularemia in Bursa, Turkey: 205 cases in 10 years. Eur. J. Epidemiol.16, 271–276 (2000).
   PubMed Web of Science ®Google Scholar
• Feldman KA, Enscore RE, Lathrop SL et al. An outbreak of primary pneumonic tularemia on Martha’s Vineyard. N. Engl. J. Med.345, 1601–1606 (2001).
   PubMed Web of Science ®Google Scholar
• Feldman KA, Stiles-Enos D, Julian K et al. Tularemia on Martha’s Vineyard: seroprevalence and occupational risk. Emerg. Infect. Dis.9, 350–354 (2003).
   PubMed Web of Science ®Google Scholar
• Christensen DR, Hartman LJ, Loveless BM et al. Detection of biological threat agents by real-time PCR: comparison of assay performance on the R.A.P.I.D., the LightCycler, and the Smart Cycler platforms. Clin. Chem.52, 141–145 (2006).
   PubMedGoogle Scholar
• Fulop M, Leslie D, Titball R. A rapid, highly sensitive method for the detection of Francisella tularensis in clinical samples using the polymerase chain reaction. Am. J. Trop. Med. Hyg.54, 364–366 (1996).
   PubMedGoogle Scholar
• Fujita O, Tatsumi M, Tanabayashi K, Yamada A. Development of a real-time PCR assay for detection and quantification of Francisella tularensis. Jpn. J. Infect. Dis.59, 46–51 (2006).
   PubMedGoogle Scholar
• Higgins JA, Hubalek Z, Halouzka J et al. Detection of Francisella tularensis in infected mammals and vectors using a probe-based polymerase chain reaction. Am. J. Trop. Med. Hyg.62, 310–318 (2000).
   PubMedGoogle Scholar
• Junhui Z, Ruifu Y, Jianchun L et al. Detection of Francisella tularensis by the polymerase chain reaction. J. Med. Microbiol.45, 477–482 (1996).
   PubMedGoogle Scholar